FLORHAM PARK, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease ...
FLORHAM PARK, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for ...
CEO Frank K. Bedu-Addo highlighted progress in the VERSATILE-003 Phase III clinical trial evaluating PDS0101 (Versamune HPV) in HPV16-positive recurrent or metastatic head and neck cancer, emphasizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results